Since August 2025, Halozyme Therapeutics has been in a holding pattern, posting a small loss of 2.1% while floating around $70.71. The stock also fell short of the S&P 500’s 6.2% gain during that ...

NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...

New specialty pharmacy and infusion suite combines compassionate nursing and infusion expertise for patients managing ...

Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...

The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the onset of migraines.

Investing.com -- Johnson & Johnson (NYSE:JNJ) announced Monday that the European Commission has approved subcutaneous Rybrevant (amivantamab) for every-three-week and every-four-week dosing schedules ...

The European Commission (EC) has approved an extension of Johnson & Johnson’s Rybrevant (amivantamab) marketing authorization ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 ...

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension ...

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

Merck started 2026 on a high note. Read why MRK stock is still one of the best choices among Big Pharma players for long-term-oriented investors.

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term ...